UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 67

Sortiert nach

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

Journal of clinical oncology, 2004-03, Vol.22 (5), p.909-918

2004

Link zum Volltext

Verfügbarkeit prüfen

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

Clinical cancer research, 2006-10, Vol.12 (19), p.5755-5763

2006

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors

Journal of clinical oncology, 2011-07, Vol.29 (21), p.2933-2940

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma

Journal of clinical oncology, 2007-09, Vol.25 (25), p.3958-3964

2007

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

Journal of clinical oncology, 2006-05, Vol.24 (15), p.2252-2260

2006

Link zum Volltext

Verfügbarkeit prüfen

Exposure–response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma

Cancer chemotherapy and pharmacology, 2023, Vol.91 (1), p.1-12

2023

Link zum Volltext

Verfügbarkeit prüfen

Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma

Cancer chemotherapy and pharmacology, 2023, Vol.91 (1), p.13-24

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma

European journal of cancer (1990), 2012-01, Vol.48 (2), p.253-262

2012

Link zum Volltext

Verfügbarkeit prüfen

Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: Pharmacokinetic considerations and clinical implications

Cancer treatment reviews, 2013-11, Vol.39 (7), p.784-792

2013

Link zum Volltext

Verfügbarkeit prüfen

Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc‐concentration modelling

British journal of clinical pharmacology, 2019-03, Vol.85 (3), p.590-600

2019

Link zum Volltext

Verfügbarkeit prüfen

Intravenous Temsirolimus in Cancer Patients: Clinical Pharmacology and Dosing Considerations

Seminars in oncology, 2009-12, Vol.36, p.S18-S25

2009

Link zum Volltext

Verfügbarkeit prüfen

A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults

Cancer chemotherapy and pharmacology, 2012-06, Vol.69 (6), p.1433-1442

2012

Link zum Volltext

Verfügbarkeit prüfen

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

Investigational new drugs, 2010-06, Vol.28 (3), p.334-342

2010

Link zum Volltext

Verfügbarkeit prüfen

Population Pharmacokinetics of CCI-779: Correlations to Safety and Pharmacogenomic Responses in Patients with Advanced Renal Cancer

Clinical pharmacology and therapeutics, 2005-01, Vol.77 (1), p.76-89

2005

Link zum Volltext

Verfügbarkeit prüfen

Exploring Relationships of Exposure, Pharmacodynamic Changes and Gene Expression to Clinical Outcome in Adults with Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin

Blood, 2015-12, Vol.126 (23), p.3698-3698

2015

Link zum Volltext

Verfügbarkeit prüfen

Effects of age and gender on the pharmacokinetics of bromfenac in healthy volunteers

The Annals of pharmacotherapy, 1997-04, Vol.31 (4), p.400

1997

Link zum Volltext

Verfügbarkeit prüfen

Comparison of 2 Doses of Intravenous (IV) Temsirolimus (Temsr) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Blood, 2016-12, Vol.128 (22), p.1775-1775

2016

Link zum Volltext

Verfügbarkeit prüfen

Chiral bioequivalence : Effect of absorption rate on racemic etodolac

Clinical pharmacokinetics, 2000-12, Vol.39 (6), p.459-469

2000

Link zum Volltext

Verfügbarkeit prüfen

Weekly Inotuzumab Ozogamicin (InO) In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)

Blood, 2013-11, Vol.122 (21), p.3906-3906

2013

Link zum Volltext

Verfügbarkeit prüfen

Phase I Study Of Inotuzumab Ozogamicin (InO) Combined With R-GDP For Relapsed/Refractory CD22+ B-Cell Non-Hodgkin Lymphoma (B-NHL)

Blood, 2013-11, Vol.122 (21), p.1821-1821

2013

Link zum Volltext

Verfügbarkeit prüfen

Intravenous Temsirolimus in Cancer Patients: Clinical Pharmacology and Dosing Considerations: Temsirolimus, a Novel mTOR Inhibitor: Its Clinical Development for Renal Cell Carcinoma and Other Tumors

Seminars in oncology, 2009, Vol.36 (6)

2009

Link zum Volltext

Verfügbarkeit prüfen

Pyrolysis and Volatilization of Cocaine

Journal of analytical toxicology, 1989-05, Vol.13 (3), p.158-162

1989

Link zum Volltext

Verfügbarkeit prüfen

The Influence of Bromfenac on the Pharmacokinetics and Pharmacodynamic Responses to Glyburide in Diabetic Subjects

Pharmacotherapy, 1997-07, Vol.17 (4), p.783-790

1997

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics of etodolac in patients with stable juvenile rheumatoid arthritis

Clinical therapeutics, 1999-10, Vol.21 (10), p.1715-1724

1999

Link zum Volltext

Verfügbarkeit prüfen

Bromfenac disposition in patients with impaired kidney function

Clinical pharmacology and therapeutics, 1997-03, Vol.61 (3), p.312-318

1997

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 67

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(64)
Mit Volltextzugriff
(60)

Publikationsform

Artikel
(66)
Buchkapitel
(1)

Sprache

Englisch
(67)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(6)
Journal Of Clinical Oncology
(6)
Cancer
(3)
Cancer Chemotherapy And Pharmacology
(3)
Aids
(2)
Cancer Research
(2)
Clinical Pharmacology And Therapeutics
(2)
Journal For Immunotherapy Of Cancer
(2)
Nature
(2)
Nature Photonics
(2)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma

A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer

Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors

Phase I/II Trial of Temsirolimus Combined With Interferon Alfa for Advanced Renal Cell Carcinoma

Phase I Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors

Exposure–response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma

Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma

Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma

Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: Pharmacokinetic considerations and clinical implications

Effect of inotuzumab ozogamicin on the QT interval in patients with haematologic malignancies using QTc‐concentration modelling

Intravenous Temsirolimus in Cancer Patients: Clinical Pharmacology and Dosing Considerations

A single-dose placebo- and moxifloxacin-controlled study of the effects of temsirolimus on cardiac repolarization in healthy adults

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

Population Pharmacokinetics of CCI-779: Correlations to Safety and Pharmacogenomic Responses in Patients with Advanced Renal Cancer

Exploring Relationships of Exposure, Pharmacodynamic Changes and Gene Expression to Clinical Outcome in Adults with Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin

Effects of age and gender on the pharmacokinetics of bromfenac in healthy volunteers

Comparison of 2 Doses of Intravenous (IV) Temsirolimus (Temsr) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Chiral bioequivalence : Effect of absorption rate on racemic etodolac

Weekly Inotuzumab Ozogamicin (InO) In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)

Phase I Study Of Inotuzumab Ozogamicin (InO) Combined With R-GDP For Relapsed/Refractory CD22+ B-Cell Non-Hodgkin Lymphoma (B-NHL)

Intravenous Temsirolimus in Cancer Patients: Clinical Pharmacology and Dosing Considerations: Temsirolimus, a Novel mTOR Inhibitor: Its Clinical Development for Renal Cell Carcinoma and Other Tumors

Pyrolysis and Volatilization of Cocaine

The Influence of Bromfenac on the Pharmacokinetics and Pharmacodynamic Responses to Glyburide in Diabetic Subjects

Pharmacokinetics of etodolac in patients with stable juvenile rheumatoid arthritis

Bromfenac disposition in patients with impaired kidney function

Suchergebnisse filtern